Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithm

Launched by SUN YAT-SEN UNIVERSITY · Jul 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help manage insulin doses for people with type 2 diabetes who are hospitalized and using an insulin pump. Researchers are testing whether an artificial intelligence (AI) program can predict the right amount of insulin better or at least as well as doctors using their experience. The goal is to see if this AI tool can safely and effectively control blood sugar levels during the hospital stay.

People who might join this study are adults with type 2 diabetes who are already using an insulin pump while in the hospital for at least 6 days but less than 30 days. Participants will be randomly placed into two groups: one where the insulin dose is decided by the AI program, and another where doctors make the decision based on their experience. All participants will have their blood sugar levels continuously monitored and receive education on managing their diabetes, including advice on diet and exercise. This study is currently looking for volunteers who meet these criteria and do not have other serious health issues that could affect the treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Meets the diagnostic criteria of type 2 diabetes mellitus in the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition).
• • 2. Insulin pump is used to control blood glucose during hospitalization, and the duration of CSII treatment period ≥6 days and \<30 days.
• Exclusion Criteria:
• • 1. Diabetes other than type 2.
• • 2. Age ≥75 years who is not suitable for intensive insulin therapy.
• • 3. Hypoglycemic regimen other than CSII treatment, such as oral hypoglycemic drugs or multiple daily insulin injections during hospitalization.
• • 4. With severe infection or uncontrolled acute complications (including ketoacidosis coma, hyperosmolar hyperglycemia, etc.) , or any condition that the researcher believes not suitable for the study.
• • 5. Severe hepatic and renal insufficiency (ALT≥5 times the upper limit of normal, eGFR\<30ml/min/1.73m2) ), or patients at the acute stage of cardiovascular and cerebrovascular diseases considered unsuitable for study.
• • 6. Pregnancy.